AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Nivaquine P 64.5mg Injection

Prescription Icon
Prescription Required

Marketer

Abbott

Salt Composition

Chloroquine (64.5mg)

Overview Nivaquine P 64.5mg Injection

Chloroquine phosphate 64.5mg injection combats malaria parasites, preventing and treating the infection. Its mechanism involves eliminating the causative parasite, halting disease progression. Administration is strictly by injection from a healthcare provider; self-injection is dangerous. Prevent mosquito bites using repellents on exposed skin and in living spaces. Wear light, protective clothing after dusk. Potential side effects include weakness, vomiting, rash, itching, stomach upset, diarrhea, appetite loss, nausea, and injection site reactions (pain, swelling, redness). Persistent side effects warrant medical attention. Diabetics should report their condition as this medication can lower blood sugar, requiring regular monitoring. Blurred vision may occur, necessitating regular eye exams. Long-term use may necessitate regular blood cell count monitoring. Report unexplained bleeding or bruising, sore throat, fever, or fatigue to your doctor.

Uses of Nivaquine P 64.5mg Injection

Managing Malaria Infections

Major Benefits of Nivaquine P 64.5mg Injection:

This medication will be administered by your healthcare provider; self-medication is strictly prohibited.

Common Side effects of Nivaquine P 64.5mg Injection:

  • Weakness
  • Rash
  • Headache
  • Dizziness
  • Vomiting
  • Nausea
  • Stomach pain
  • Loss of appetite
  • Diarrhea

How to use Nivaquine P 64.5mg Injection:

This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.

How Nivaquine P 64.5mg Injection works:

Chloroquine phosphate injection (64.5mg) combats malaria, its antiparasitic action stemming from elevated blood heme levels. This heightened heme concentration proves toxic to the malaria parasite, resulting in its demise and halting disease progression.

SAFETY ADVICE

AlcoholAlcoholCONSULT YOUR DOCTOR

Alcohol consumption alongside Nivaquine P 64.5mg Injection may pose unknown risks. Seek medical advice before combining them.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Nivaquine P 64.5mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescription. Physician consultation is advised.

Breast feedingBreast feedingSAFE IF PRESCRIBED

Administering Nivaquine P 64.5mg Injection while breastfeeding presents minimal risk. Research in humans indicates negligible transfer of the medication into breast milk, posing no apparent threat to the infant.

DrivingDrivingUNSAFE

Administration of Nivaquine P 64.5mg Injection may induce adverse reactions that impair driving capabilities. Blurred vision or difficulty focusing, potential side effects of Nivaquine P 64.5mg Injection, can similarly compromise safe driving.

KidneyKidneyCAUTION

Patients with kidney impairment should use Nivaquine P 64.5mg Injection cautiously, potentially requiring dosage modification. Medical advice is recommended.

LiverLiverCAUTION

Patients with liver conditions should exercise caution when using Nivaquine P 64.5mg Injection. Dosage modification may be necessary; physician consultation is recommended. Routine liver function tests are advisable during treatment.

What if you forget to take Nivaquine P 64.5mg Injection :

NA

Facts to Know About Nivaquine P 64.5mg Injection

LabelValue
Type of Compound A compound derived from 4-aminoquinoline.
Addictive None.
Type of Medication Eye drops
Mechanism of Action Malaria drugs: Aminoquinoline class

FAQs on Nivaquine P 64.5mg Injection

Chloroquine phosphate injection (64.5 mg) is an antimalarial drug indicated for malaria prophylaxis and treatment.
Malaria symptoms can emerge within a week of an infected mosquito bite. The incubation period typically ranges from seven to eighteen days post-infection. Early malaria symptoms mimic influenza, encompassing chills and fever, myalgia, nausea, cephalalgia, and diarrhea.
Prolonged use of Nivaquine P 64.5mg Injection, as directed by your physician, necessitates regular eye examinations. This is a precaution due to the chloroquine content, which can potentially induce blurred vision, impaired reading ability (manifested as the appearance of disappearing words), and, infrequently, retinopathy with extended treatment.
Consult your physician regarding any history of psoriasis prior to administering Nivaquine P 64.5mg Injection, as it could potentially exacerbate the condition.
Abdominal discomfort, queasiness, emesis, and cephalalgia are frequently reported adverse reactions associated with this medication. Ingesting the medication with food may often mitigate these effects.
Insufficient clinical evidence supports chloroquine's efficacy against COVID-19. Consequently, using Nivaquine P 64.5mg Injection for this purpose without physician consultation is not recommended.
Allow at least four hours to elapse between taking an antacid and other medications.
Both hydroxychloroquine and chloroquine initially received regulatory approval for malaria treatment. Hydroxychloroquine, however, exhibits a more favorable side effect profile compared to chloroquine. Consequently, hydroxychloroquine enjoys greater current usage. Furthermore, hydroxychloroquine's therapeutic applications extend to rheumatoid arthritis and lupus, unlike chloroquine.
Mosquito-borne malaria can be avoided through preventative measures such as wearing protective clothing, employing mosquito nets, and utilizing insect repellents. Consult your physician regarding the necessity of prophylactic antimalarial medication. If prescribed, adhere strictly to the correct dosage and complete the entire course of treatment.
Chloroquine phosphate injection, 64.5mg, is an antimalarial drug indicated for malaria prophylaxis and treatment.
Malaria symptoms can emerge within a week of an infected mosquito bite. More commonly, these symptoms manifest between seven and eighteen days post-infection. Initial symptoms resemble influenza, encompassing chills, fever, myalgia, nausea, cephalalgia, and diarrhea.
Prolonged use of Nivaquine P 64.5mg Injection, as directed by your physician, necessitates regular eye examinations. This is due to the potential for chloroquine, a component of this medication, to induce blurred vision, reading difficulties (characterized by apparent word loss), and, infrequently, retinopathy with extended administration.
Consult your physician about any history of psoriasis prior to administering Nivaquine P 64.5mg Injection, as it could potentially exacerbate the condition.
Abdominal discomfort, queasiness, emesis, and cephalalgia are among the frequently reported adverse reactions to this medication. Ingesting the medication with food may often mitigate these effects.
Insufficient clinical evidence supports the use of chloroquine in COVID-19 treatment. Consequently, administering Nivaquine P 64.5mg Injection for this purpose should only occur under a physician's guidance.
Allow at least four hours between taking an antacid and other medications.
Both hydroxychloroquine and chloroquine initially gained approval as malaria treatments. Hydroxychloroquine, however, exhibits a superior safety profile, producing fewer adverse reactions compared to chloroquine. Consequently, hydroxychloroquine enjoys more widespread current use. Furthermore, hydroxychloroquine holds additional approvals for rheumatoid arthritis and lupus, unlike chloroquine.
Mosquito-borne malaria can be avoided through preventative measures such as wearing protective clothing, employing mosquito nets, and using insect repellent. Consult your physician regarding the necessity of antimalarial medication. If prescribed, adhere strictly to the dosage and complete the entire course of treatment.
Nivaquine P 64.5mg Inject...
12
MRP 14
16% off